Abstract:At the Washington "2nd International Workshop on Genotoxicity Testing" (25-26 March 1999) current methodologies and data for the in vitro micronucleus test were reviewed. As a result, guidelines for the conduct of specific aspects of the protocol were developed. Agreement was achieved on the following topics: choice of cells, slide preparation, analysis of micronuclei, toxicity, use of cytochalasin-B, number of doses, and treatment/harvest times [Environ. Mol. Mutagen. 35 (2000) 167]. Because there were a number of important in vitro micronucleus validation studies in progress, it was not possible to design a definitive, internationally harmonized protocol at that time. These studies have now been completed and the data were reviewed at the Plymouth "3rd International Workshop on Genotoxicity Testing" (28-29 June 2002). Data from studies coordinated by the French Society of Genetic Toxicology, Japanese collaborative studies, European pharmaceutical industry validation studies, along with data from Lilly Research Laboratories were used to prepare conclusions on the main aspects of the in vitro micronucleus protocol. In this paper, the consensus agreements on the protocol for performing the in vitro micronucleus assay are presented. The major recommendations concern: 1. Demonstration of cell proliferation: both cell lines and lymphocytes can be used, but demonstration of cell proliferation in both control and treated cells is compulsory for the acceptance of the test. 2. Assessment of toxicity and dose range finding: assessment of toxicity should be performed by determining cell proliferation, e.g. increased cell counts (CC) or population doubling (PD) without cytochalasin-B, or e.g. cytokinesis-block proliferation index with cytochalasin-B; and by determining other markers for cytotoxicity (confluency, apoptosis, necrosis) which can provide valuable additional information. 3. Treatment schedules for cell lines and lymphocytes. 4. Choice of positive controls: without S9-mix both a clastogen (e.g. mitomycin C or bleomycin) and an aneugen (e.g. colchicine) should be included as positive controls and a clastogen that requires S9 for activity when S9-mix is used (e.g. dimethylnitrosamine, or cyclophosphamide in those cell types that cannot activate this agent directly). 5. Duplicate cultures and number of cells to be scored. 6. Repeat experiments: in lymphocytes, for each experiment blood from 2 different healthy young and non-smoking donors should be compared. In cell lines, the experiments need only to be repeated if the first one is negative. 7. Statistics: statistical significance should not be the sole factor for determining positive results. Biological meaning should serve as a guideline. Examples of statistical analyses are given.

Regulatory requirements for genotoxicity assessment of plant protection product active ingredients, impurities, and metabolites

[The Application of Transgenic Plant in Evaluating the Genotoxicity of Environmental Contaminants].

Genotoxicity testing approaches for the safety assessment of substances used in food contact materials prior to their authorization in the European Union

Evaluation and Control of Genotoxic Impurities in Active Pharmaceutical Ingredients

Review of Current and “omics” Methods for Assessing the Toxicity (genotoxicity, Teratogenicity and Nephrotoxicity) of Herbal Medicines and Mushrooms

Assessment of the three-test genetic toxicology battery for groundwater metabolites

Regulation of genotoxic and carcinogenic impurities in drug substances and products

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity

Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective

The Assessment of Impurities for Genotoxic Potential and Subsequent Control in Drug Substance and Drug Product

Guidance for the use and interpretation of assays for monitoring anti-genotoxicity

Genotoxicity Assessment of Nanomaterials: Recommendations on Best Practices, Assays, and Methods

GENOTOXIC IMPURITIES: AN IMPORTANT REGULATORY ASPECT

Common Considerations for Genotoxicity Assessment of Nanomaterials

Overview of Genotoxic Impurities in Pharmaceutical Development

Genotoxicity Testing and Recent Advances

Risk Assessment of Genotoxic Impurities in Marketed Compounds Administered over a Short-Term Duration: Applications to Oncology Products and Implications for Impurity Control Limits

Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control

Evaluation of the herbicide glyphosate, (aminomethyl)phosphonic acid, and glyphosate-based formulations for genotoxic activity using in vitro assays

A comparison of the EU regulatory approach to directed mutagenesis with that of other jurisdictions, consequences for international trade and potential steps forward

Report from the in vitro micronucleus assay working group